Summary:
- The article reports that China's National Medical Products Administration (NMPA) has approved Alphamab Oncology's KN046 drug for the treatment of certain types of advanced solid tumors.
- KN046 is a bispecific antibody that targets both PD-L1 and CTLA-4, two important immune checkpoint proteins involved in cancer development.
- The approval of KN046 by the NMPA is a significant milestone for Alphamab Oncology, as it paves the way for the commercialization of this novel cancer treatment in the Chinese market.